Inflammatory bowel diseases (IBDs) affecting the colon [Crohn's disease (CD) and ulcerative colitis (UC)] are associated with an increased risk of colorectal cancer (CRC). Our previous work using oligonucleotide array data indicated that SMAD2 was significantly underexpressed in UC dysplastic tissue compared to benign UC. The aim of this current study was to determine whether single nucleotide polymorphisms (SNPs) within the SMAD2 gene are associated with IBD dysplasia/cancer. We performed an SNP haplotype-based case-control association study. Leukocyte DNA was obtained from 489 unrelated Caucasians (158 UC, 175 CD, 71 CRC, 85 controls). Eleven SNPs were genotyped. All 11 SNPs were in Hardy-Weinberg equilibrium in the control population. Strong linkage disequilibrium was observed among nearly all SMAD2 SNPs. There were no significant associations between SMAD2 allele or haplotype frequencies. Power calculations indicated good power for single-marker analysis (>0.8) and reasonably good power against effects of 0.1–0.15 for haplotype analysis. SMAD2 SNPs were not associated with the development of IBD dysplasia/cancer. This incongruity between our previous microarray data and the findings from this genotype study may be attributed to mechanisms such as alternative splicing of pre-mRNA SMAD2 and/or cross talk with other cellular pathways.
BenhattarJ., SaragaE.. Molecular genetics of dysplasia in ulcerative colitis.Eur J Cancer1995; 31A: 1171–3.
2.
CrawfordN.P., ColliverD.W., GalandiukS.. Tumor markers and colorectal cancer: utility in management.J Surg Oncol2003; 84: 239–48.
3.
KarlénP., LofbergR., BroströmO.. Sialyl-Tn antigen as a marker of colon cancer risk in ulcerative colitis: relation to dysplasia and DNA aneuploidy.Gastroenterology1998; 115: 1395–404.
4.
AhlquistD.A., SkoletskyJ.E., BoyntonK.A.. Colorectal cancer screening by detection of altered human DNA in stool: feasibility of a multitarget assay panel.Gastroenterology2000; 119: 1219–27.
5.
EkbomA., HelmickC., ZackM.. Increased risk of large-bowel cancer in Crohn's disease with colonic involvement.Lancet1990; 336: 357–9.
6.
LangholzE., MunkholmP., DavidsenM., BinderV.. Colorectal cancer risk and mortality in patients with ulcerative colitis.Gastroenterology1992; 103: 1444–51.
UllmanT.A., LoftusE.V.Jr, KakarS., BurgartL.J., SandbornW.J., TremaineW.J.. The fate of low grade dysplasia in ulcerative colitis.Am J Gastroenterol2002; 97: 922–7.
9.
ViscidoA., BagnardiV., SturnioloG.C.. Survival and causes of death in Italian patients with ulcerative colitis. A GISC nationwide study.Dig Liver Dis2001; 33: 686–92.
10.
GillenC.D., WalmsleyR.S., PriorP., AndrewsH.A., AllanR.N.. Ulcerative colitis and Crohn's disease: a comparison of the colorectal cancer risk in extensive colitis.Gut1994; 35: 1590–2.
11.
BroomeU., LofbergR., VeressB., ErikssonL.S.. Primary sclerosing cholangitis and ulcerative colitis: evidence for increased neoplastic potential.Hepatology1995; 22: 1404–8.
12.
BernsteinC.N., BlanchardJ.F., KliewerE., WajdaA.. Cancer risk in patients with inflammatory bowel disease: a population-based study.Cancer2001; 91: 854–62.
13.
KrokK.L., LichtensteinG.R.. Colorectal cancer in inflammatory bowel disease.Curr Opin Gastroenterol2004; 20: 43–8.
14.
FearonE.R., VogelsteinB.. A genetic model for colorectal tumorigenesis.Cell1990; 61: 759–67.
15.
FearonE.R., ChoK.R., NigroJ.M.. Identification of a chromosome 18q gene that is altered in colorectal cancers.Science1990; 247: 49–56.
16.
TerdimanJ.P., AustD.E., ChangC.G.. High resolution analysis of chromosome 18 alterations in ulcerative colitis-related colorectal cancer.Cancer Genet Cytogenet2002; 136: 129–37.
17.
XuJ., AttisanoL.. Mutations in the tumor suppressors Smad2 and Smad4 inactivate transforming growth factor beta signaling by targeting Smads to the ubiquitin-proteasome pathway.Proc Natl Acad Sci U S A2000; 97: 4820–5.
18.
XieW., RimmD.L., LinY., ShihW.J., ReissM.. Loss of Smad signaling in human colorectal cancer is associated with advanced disease and poor progression.Cancer J2003; 9: 302–12.
19.
LiF., CaoY., TownsendC.M.. TGF-beta signaling in colon cancer cells.World J Surg2005; 29: 306–11.
20.
Woodford-RichensK.L., RowanA.J., GormanP.. SMAD4 mutations in colorectal cancer probably occur before chromosomal instability, but after divergence of the microsatellite instability pathway.Proc Natl Acad Sci U S A2001; 98: 9719–23.
MelvilleD.M., JassJ.R., MorsonB.C.. Observer study of the grading of dysplasia in ulcerative colitis: comparison with clinical outcome.Hum Pathol1989; 20: 1008–14.
23.
OdzeR.D., GoldblumJ., NoffsingerA., AlsaighN., RybickiL.A., FogtF.. Interobserver variability in the diagnosis of ulcerative colitis-associated dysplasia by telepathology.Mod Pathol2002; 15: 379–86.
24.
RothM.P., PetersenG.M., McElreeC., FeldmanE., RotterJ.I.. Geographic origins of Jewish patients with inflammatory bowel disease.Gastroenterology1989; 97: 900–4.
25.
ZlotogoraJ., ZimmermanJ., RachmilewitzD.. Crohn's disease in Ashkenazi Jews.Gastroenterology1990; 99: 286–7.
26.
ProbertC.S., JayanthiV., HughesA.O., ThompsonJ.R., WicksA.C., MayberryJ.F.. Prevalence and family risk of ulcerative colitis and Crohn's disease: an epidemiological study among Europeans and south Asians in Leicestershire.Gut1993; 34: 1547–51.
27.
BasuD., LopezI., KulkarniA., SellinJ.H.. Impact of race and ethnicity on inflammatory bowel disease.Am J Gastroenterol2005; 100: 2254–61.
28.
SebastianiP., LazarusR., WeissS.T., KunkelL.M., KohaneI.S., RamoniM.F.. Minimal haplotype tagging.Proc Natl Acad Sci U S A2003; 100: 9900–5.
29.
BenjaminiY., HochbergY.. Controlling the false discovery rate: a practical and powerful approach to multiple testing.J R Stat Soc B1995; 57: 289–300.
30.
MarthG.T., KorfI., YandellM.D.. A general approach to single nucleotide polymorphism discovery.Nat Genet1999; 23: 452–6.
DerynckR., ZhangY.E.. Smad-dependent and Smad-independent pathways in TGF-beta family signalling.Nature2003; 425: 577–84.
33.
ItohS., ItohF., GoumansM.J., ten DijkeP.. Signaling of transforming growth factor-beta family members through Smad proteins.Eur J Biochem2000; 267: 6954–67.
34.
MoustakasA., SouchelnytskyiS., HeldinC.H.. Smad regulation in TGF-beta signal transduction.J Cell Sci2001; 114: 4359–69.
35.
JavelaudD., MauvielA.. Crosstalk mechanisms between the mitogen- activated protein kinase pathways and Smad signaling downstream of TGF-beta: implications for carcinogenesis.Oncogene2005; 24: 5742–50.
36.
DerynckR., AkhurstR.J., BalmainA.. TGF-beta signaling in tumor suppression and cancer progression.Nat Genet2001; 29: 117–29.
37.
YagiK., GotoD., HamamotoT., TakenoshitaS., KatoM., MiyazonoK.. Alternatively spliced variant of Smad2 lacking exon 3. Comparison with wild-type Smad2 and Smad3.J Biol Chem1999; 274: 703–9.
38.
MoriyamaT., MatsumotoT., NakamuraS.. Hypermethylation of p14 (ARF) may be predictive of colitic cancer in patients with ulcerative colitis.Dis Colon Rectum2007; 50: 1384–92.
39.
MonzoM., NavarroA., BandresE.. Overlapping expression of microRNAs in human embryonic colon and colorectal cancer.Cell Res2008; 18: 823–33.
